Amylyx Pharmaceuticals, Inc. (AMLX)
- Previous Close
2.1200 - Open
2.1100 - Bid 2.2000 x 200
- Ask 2.2500 x 100
- Day's Range
2.0900 - 2.2300 - 52 Week Range
1.5750 - 22.0240 - Volume
407,838 - Avg. Volume
1,620,868 - Market Cap (intraday)
151.143M - Beta (5Y Monthly) -0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4600 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
amylyx.comRecent News: AMLX
View MorePerformance Overview: AMLX
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMLX
View MoreValuation Measures
Market Cap
150.80M
Enterprise Value
-155.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
0.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-55.52%
Return on Assets (ttm)
-28.28%
Return on Equity (ttm)
-51.22%
Revenue (ttm)
298.76M
Net Income Avi to Common (ttm)
-165.87M
Diluted EPS (ttm)
-2.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
309.81M
Total Debt/Equity (mrq)
1.20%
Levered Free Cash Flow (ttm)
-12.66M